Who are Bendamustine, Velcade and Dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bendamustine-velcade-and-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bendamustine, Velcade and Dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bendamustine, Velcade and Dexamethasone (Bendamustine, Velcade and Dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent, Proteasome inhibitor, Corticosteroid. Area: Oncology.

phase 2 Alkylating agent, Proteasome inhibitor, Corticosteroid DNA, Proteasome, Glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bendamustine, Velcade and Dexamethasone (Bendamustine, Velcade and Dexamethasone) — Intergroupe Francophone du Myelome. Bendamustine is a nitrogen mustard alkylating agent that cross-links DNA, Velcade is a proteasome inhibitor that blocks the 26S proteasome, Dexamethasone is a corticosteroid that inhibits phospholipase A2.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bendamustine, Velcade and Dexamethasone TARGET	Bendamustine, Velcade and Dexamethasone	Intergroupe Francophone du Myelome	phase 2	Alkylating agent, Proteasome inhibitor, Corticosteroid	DNA, Proteasome, Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent, Proteasome inhibitor, Corticosteroid class)

Intergroupe Francophone du Myelome · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bendamustine, Velcade and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/bendamustine-velcade-and-dexamethasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab